Xyrem sodium oxybate: Phase III data; NDA under review by FDA

ORPH said data from a two-week, double-blind, U.S. Phase III study in 55 patients showed a median increase of 21 cataplexy attacks in the placebo group compared to the Xyrem-treated group (p<0.001). P...